1887

Abstract

The objective of this study was to develop an optimal vaccination strategy for (BVDV). The E2 protein of BVDV plays a major protective role against BVDV infection. In order to be able to compare DNA, protein and DNA prime–protein boost regimens, a plasmid was constructed encoding a secreted form of the NADL strain E2 protein (pMASIA-tPAsΔE2). Furthermore, a pure secreted recombinant ΔE2 (rΔE2) protein was produced. The rΔE2 protein was formulated with a combination of Emulsigen and CpG oligodeoxynucleotide. Groups of calves were immunized with pMASIA-tPAsΔE2 or with rΔE2, or first with pMASIA-tPAsΔE2 and then with rΔE2. To evaluate the protection against BVDV, calves were challenged with BVDV strain NY-1 after the last immunization. Although all immunized calves developed humoral and cellular immune responses, the antibody responses in the DNA prime–protein boost group were stronger than those elicited by either the DNA vaccine or the protein vaccine. In particular, E2-specific antibody titres were enhanced significantly after boosting the ΔE2 DNA-primed calves with rΔE2 protein. Moreover, protection against BVDV challenge was obtained in the calves treated with the DNA prime–protein boost vaccination regimen, as shown by a significant reduction in weight loss, viral excretion and lymphopenia, compared with the unvaccinated calves and the animals immunized with the DNA or protein only. These results demonstrate the advantage of a DNA prime–protein boost vaccination approach in an outbred species.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81737-0
2006-10-01
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/10/2971.html?itemId=/content/journal/jgv/10.1099/vir.0.81737-0&mimeType=html&fmt=ahah

References

  1. Ballas, Z. K., Rasmussen, W. L. & Krieg, A. M. ( 1996; ). Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157, 1840–1845.
    [Google Scholar]
  2. Barnett, S. W., Rajasekar, S., Legg, H., Doe, B., Fuller, D. H., Haynes, J. R., Walker, C. M. & Steimer, K. S. ( 1997; ). Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15, 869–873.[CrossRef]
    [Google Scholar]
  3. Bolin, S. R. ( 1993; ). Immunogens of bovine viral diarrhea virus. Vet Microbiol 37, 263–271.[CrossRef]
    [Google Scholar]
  4. Bolin, S. R. ( 1995; ). Control of bovine viral diarrhea infection by use of vaccination. Vet Clin North Am Food Anim Pract 11, 615–625.
    [Google Scholar]
  5. Bolin, S. R. & Ridpath, J. F. ( 1990; ). Frequency of association of noncytopathic bovine viral diarrhea virus with bovine neutrophils and mononuclear leukocytes before and after treatment with trypsin. Am J Vet Res 51, 1847–1851.
    [Google Scholar]
  6. Bolin, S. R. & Ridpath, J. F. ( 1996; ). Glycoprotein E2 of bovine viral diarrhea virus expressed in insect cells provides calves limited protection from systemic infection and disease. Arch Virol 141, 1463–1477.[CrossRef]
    [Google Scholar]
  7. Brownlie, J. ( 1990; ). The pathogenesis of bovine virus diarrhoea virus infections. Rev Sci Tech 9, 43–59.
    [Google Scholar]
  8. Bruschke, C. J. M., van Oirschot, J. T. & van Rijn, P. A. ( 1999; ). An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep. Vaccine 17, 1983–1991.[CrossRef]
    [Google Scholar]
  9. Cardon, L. R., Burge, C., Clayton, D. A. & Karlin, S. ( 1994; ). Pervasive CpG suppression in animal mitochondrial genomes. Proc Natl Acad Sci U S A 91, 3799–3803.[CrossRef]
    [Google Scholar]
  10. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. ( 1997; ). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623–1631.[CrossRef]
    [Google Scholar]
  11. Collett, M. S., Larson, R., Belzer, S. K. & Retzel, E. ( 1988; ). Proteins encoded by bovine viral diarrhea virus: the genomic organization of a pestivirus. Virology 165, 200–208.[CrossRef]
    [Google Scholar]
  12. Collett, M. S., Wiskerchen, M., Welniak, E. & Belzer, S. K. ( 1991; ). Bovine viral diarrhea virus genomic organization. Arch Virol Suppl 3, 19–27.
    [Google Scholar]
  13. Davis, H. L. ( 2000; ). Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 247, 171–183.
    [Google Scholar]
  14. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. ( 1998; ). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870–876.
    [Google Scholar]
  15. Dean, H. J., Hunsaker, B. D., Bailey, O. D. & Wasmoen, T. ( 2003; ). Prevention of persistent infection in calves by vaccination of dams with noncytopathic type-1 modified-live bovine viral diarrhea virus prior to breeding. Am J Vet Res 64, 530–537.[CrossRef]
    [Google Scholar]
  16. Dégano, P., Schneider, J., Hannan, C. M., Gilbert, S. C. & Hill, A. V. S. ( 1999; ). Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18, 623–632.[CrossRef]
    [Google Scholar]
  17. Donis, R. O. ( 1995; ). Molecular biology of bovine viral diarrhea virus and its interactions with the host. Vet Clin North Am Food Anim Pract 11, 393–423.
    [Google Scholar]
  18. Duffell, S. J. & Harkness, J. W. ( 1985; ). Bovine virus diarrhoea-mucosal disease infection in cattle. Vet Rec 117, 240–245.[CrossRef]
    [Google Scholar]
  19. Dunachie, S. J. & Hill, A. V. S. ( 2003; ). Prime–boost strategies for malaria vaccine development. J Exp Biol 206, 3771–3779.[CrossRef]
    [Google Scholar]
  20. Estcourt, M. J., Ramsay, A. J., Brooks, A., Thomson, S. A., Medveckzy, C. J. & Ramshaw, I. A. ( 2002; ). Prime–boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 14, 31–37.[CrossRef]
    [Google Scholar]
  21. Fairbanks, K. K., Rinehart, C. L., Ohnesorge, W. C., Loughin, M. M. & Chase, C. C. ( 2004; ). Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc 225, 1898–1904.[CrossRef]
    [Google Scholar]
  22. Grooms, D. L., Brock, K. V. & Ward, L. A. ( 1998; ). Detection of cytopathic bovine viral diarrhea virus in the ovaries of cattle following immunization with a modified live bovine viral diarrhea virus vaccine. J Vet Diagn Invest 10, 130–134.[CrossRef]
    [Google Scholar]
  23. Harpin, S., Talbot, B., Mbikay, M. & Elazhary, Y. ( 1997; ). Immune response to vaccination with DNA encoding the bovine viral diarrhea virus major glycoprotein gp53 (E2). FEMS Microbiol Lett 146, 229–234.[CrossRef]
    [Google Scholar]
  24. Harpin, S., Hurley, D. J., Mbikay, M., Talbot, B. & Elazhary, Y. ( 1999; ). Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhoea virus major glycoprotein E2. J Gen Virol 80, 3137–3144.
    [Google Scholar]
  25. Hartmann, G. & Krieg, A. M. ( 2000; ). Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164, 944–953.[CrossRef]
    [Google Scholar]
  26. Hartmann, G., Weeratna, R. D., Ballas, Z. K. & 9 other authors ( 2000; ). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164, 1617–1624.[CrossRef]
    [Google Scholar]
  27. Ioannou, X. P., Gomis, S. M., Karvonen, B., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2002a; ). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21, 127–137.[CrossRef]
    [Google Scholar]
  28. Ioannou, X. P., Griebel, P., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2002b; ). The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76, 9002–9010.[CrossRef]
    [Google Scholar]
  29. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C. & Vogel, J. C. ( 1998; ). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161, 3042–3049.
    [Google Scholar]
  30. Kamstrup, S., Roensholt, L., Jensen, M. H. & Dalsgaard, K. ( 1999; ). Production of a highly immunogenic subunit ISCOM vaccine against bovine viral diarrhea virus. Vaccine 17, 1057–1064.[CrossRef]
    [Google Scholar]
  31. Kelling, C. L. ( 2004; ). Evolution of bovine viral diarrhea virus vaccines. Vet Clin North Am Food Anim Pract 20, 115–129.[CrossRef]
    [Google Scholar]
  32. Kelling, C. L., Hunsaker, B. D., Steffen, D. J., Topliff, C. L., Abdelmagid, O. Y. & Eskridge, K. M. ( 2005; ). Characterization of protection from systemic infection and disease by use of a modified-live noncytopathic bovine viral diarrhea virus type 1 vaccine in experimentally infected calves. Am J Vet Res 66, 1785–1791.[CrossRef]
    [Google Scholar]
  33. Klinman, D. M. ( 2003; ). CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2, 305–315.[CrossRef]
    [Google Scholar]
  34. Kowalski, J. K., Gilbert, S. A., van Drunen Littel-van den Hurk, S., van den Hurk, J. V., Babiuk, L. A. & Zamb, T. J. ( 1993; ). Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 11, 1100–1107.[CrossRef]
    [Google Scholar]
  35. Krieg, A. M. & Davis, H. L. ( 2001; ). Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3, 15–24.
    [Google Scholar]
  36. Krieg, A. M., Yi, A.-K., Schorr, J. & Davis, H. L. ( 1998; ). The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6, 23–27.[CrossRef]
    [Google Scholar]
  37. Lasaro, M. O., Alves, A. M., Guillobel, H. C., Almeida, D. F. & Ferreira, L. C. ( 1999; ). New vaccine strategies against enterotoxigenic Escherichia coli. II: Enhanced systemic and secreted antibody responses against the CFA/I fimbriae by priming with DNA and boosting with a live recombinant Salmonella vaccine. Braz J Med Biol Res 32, 241–246.
    [Google Scholar]
  38. Liang, R., van den Hurk, J. V., Zheng, C., Yu, H., Pontarollo, R. A., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2005; ). Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 23, 5252–5262.[CrossRef]
    [Google Scholar]
  39. Moennig, V., Eicken, K., Flebbe, U., Frey, H.-R., Grummer, B., Haas, L., Greiser-Wilke, I. & Liess, B. ( 2005; ). Implementation of two-step vaccination in the control of bovine viral diarrhoea (BVD). Prev Vet Med 72, 109–114.[CrossRef]
    [Google Scholar]
  40. Mossman, S. P., Pierce, C. C., Robertson, M. N. & 12 other authors ( 1999; ). Immunization against SIVmne in macaques using multigenic DNA vaccines. J Med Primatol 28, 206–213.[CrossRef]
    [Google Scholar]
  41. Nakamura, Y., Gojobori, T. & Ikemura, T. ( 2000; ). Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 28, 292.[CrossRef]
    [Google Scholar]
  42. Nobiron, I., Thompson, I., Brownlie, J. & Collins, M. E. ( 2003; ). DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge. Vaccine 21, 2082–2092.[CrossRef]
    [Google Scholar]
  43. Pontarollo, R. A., Babiuk, L. A., Hecker, R. & van Drunen Littel-van den Hurk, S. ( 2002; ). Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 83, 2973–2981.
    [Google Scholar]
  44. Raggo, C., Habermehl, M., Babiuk, L. A. & Griebel, P. ( 2000; ). The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-γ. J Gen Virol 81, 2665–2673.
    [Google Scholar]
  45. Robinson, H. L., Montefiori, D. C., Johnson, R. P. & 14 other authors ( 1999; ). Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526–534.[CrossRef]
    [Google Scholar]
  46. Roeder, P. L. & Harkness, J. W. ( 1986; ). BVD virus infection: prospects for control. Vet Rec 118, 143–147.
    [Google Scholar]
  47. Rümenapf, T., Unger, G., Strauss, J. H. & Thiel, H.-J. ( 1993; ). Processing of the envelope glycoproteins of pestiviruses. J Virol 67, 3288–3294.
    [Google Scholar]
  48. Schneider, J., Gilbert, S. C., Blanchard, T. J. & 7 other authors ( 1998; ). Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4, 397–402.[CrossRef]
    [Google Scholar]
  49. Schneider, J., Langermans, J. A. M., Gilbert, S. C. & 10 other authors ( 2001; ). A prime–boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19, 4595–4602.[CrossRef]
    [Google Scholar]
  50. Song, M. K., Lee, S. W., Suh, Y. S., Lee, K. J. & Sung, Y. C. ( 2000; ). Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 74, 2920–2925.[CrossRef]
    [Google Scholar]
  51. Ulmer, J. B., Donnelly, J. J., Parker, S. E. & 8 other authors ( 1993; ). Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749.[CrossRef]
    [Google Scholar]
  52. van Drunen Littel-van den Hurk, S., Braun, R. P., Lewis, P. J., Karvonen, B. C., Baca-Estrada, M. E., Snider, M., McCartney, D., Watts, T. & Babiuk, L. A. ( 1998; ). Intradermal immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in cattle. J Gen Virol 79, 831–839.
    [Google Scholar]
  53. Vassilev, V. B., Gil, L. H. V. G. & Donis, R. O. ( 2001; ). Microparticle-mediated RNA immunization against bovine viral diarrhea virus. Vaccine 19, 2012–2019.[CrossRef]
    [Google Scholar]
  54. Wang, B., Ugen, K. E., Srikantan, V. & 7 other authors ( 1993; ). Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90, 4156–4160.[CrossRef]
    [Google Scholar]
  55. Weiland, E., Stark, R., Haas, B., Rümenapf, T., Meyers, G. & Thiel, H.-J. ( 1990; ). Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol 64, 3563–3569.
    [Google Scholar]
  56. Xiang, Z. Q., Spitalnik, S., Tran, M., Wunner, W. H., Cheng, J. & Ertl, H. C. J. ( 1994; ). Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199, 132–140.[CrossRef]
    [Google Scholar]
  57. Young, N. J., Thomas, C. J., Thompson, I., Collins, M. E. & Brownlie, J. ( 2005; ). Immune responses to non-structural protein 3 (NS3) of bovine viral diarrhoea virus (BVDV) in NS3 DNA vaccinated and naturally infected cattle. Prev Vet Med 72, 115–120.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81737-0
Loading
/content/journal/jgv/10.1099/vir.0.81737-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error